Pneumococcal polysaccharide-protein conjugate composition

US11191822B2 · kind B2 · utility

Assignee

• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Peter H. Seeberger · Potsdam, DE
• Claney Lebev Pereira · Berlin, DE
• Madhu Emmadi · Berlin, DE
• Sharavathi Guddehalli Parameswarappa · Berlin, DE
• Adam Calow · Bristol, GB
• Petra Menova · Praha, CZ
• Marilda P. Lisboa · Berlin, DE
• Christopher Martin · Berlin, DE
• Benjamin Schumann · Berlin, DE
• Fei Xu · Monet, US
• Naeem Khan · Berlin, DE
• Paulina Kaplonek · Berlin, DE
• Lennart Lykke · Copenhagen, DK

Key dates

• Filing date: Jun 22, 2017
• Grant date: Dec 7, 2021
• Expiry date: Jun 22, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/62
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to immunogenic compositions comprising a conjugate of a saccharide from Streptococcus pneumoniae serotype 8 and a carrier protein, and a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to CRM197 carrier protein, or a mixture consisting of capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F individually conjugated to a carrier protein, wherein the capsular polysaccharides from Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, and 23F are individually conjugated to protein D, the capsular polysaccharide from Streptococcus pneumoniae serotype 18C is conjugated to tetanus toxoid and the capsular polysaccharide from Streptococcus pneumoniae serotype 19F is conjugated to diphtheria toxoid. Said compositions are useful for the prevention and/or treatment of diseases caused by Streptococcus pneumoniae.